Milestone Pharmaceuticals Inc
MIST2.070USD
-0.080-3.72%
收盘 12/22, 16:00（美东）报价延迟15分钟
176.30M总市值
亏损市盈率 TTM
关于 Milestone Pharmaceuticals Inc 公司
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Milestone Pharmaceuticals Inc简介
公司代码MIST
公司名称Milestone Pharmaceuticals Inc
上市日期May 09, 2019
CEOOliveto (Joseph)
员工数量33
证券类型Ordinary Share
年结日May 09
公司地址420-1111 boul. Dr.-Frederik-Philips
城市MONTREAL
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编H4M 2X6
电话15143360444
网址https://www.milestonepharma.com
公司代码MIST
上市日期May 09, 2019
CEOOliveto (Joseph)
Milestone Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Independent Director
Independent Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Morgan Stanley & Co. LLC
3.09%
其他
71.09%
持股股东
持股股东
占比
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Morgan Stanley & Co. LLC
3.09%
其他
71.09%
股东类型
持股股东
占比
Investment Advisor
16.23%
Hedge Fund
14.25%
Research Firm
5.04%
Investment Advisor/Hedge Fund
3.94%
Private Equity
3.78%
Individual Investor
3.57%
Venture Capital
1.22%
Family Office
1.17%
Bank and Trust
0.02%
其他
50.77%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
99
19.38M
22.80%
-5.64M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
2023Q2
108
21.35M
63.87%
-11.78M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Simplify Asset Management Inc
990.00K
1.16%
+140.00K
+16.47%
Jun 30, 2025
Trails Edge Capital Partners LP
5.33M
6.27%
+5.33M
--
Jul 14, 2025
Morgan Stanley & Co. LLC
817.82K
0.96%
-148.10K
-15.33%
Jun 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
RTW Investments L.P.
2.51M
2.95%
--
--
Jun 30, 2025
Propel Bio Management, LLC
1.79M
2.11%
+340.00K
+23.42%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
Simplify Propel Opportunities ETF
8.04%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
占比8.04%
SPDR S&P International Small Cap ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Milestone Pharmaceuticals Inc的前五大股东是谁？
Milestone Pharmaceuticals Inc 的前五大股东如下：
Simplify Asset Management Inc持有股份：990.00K，占总股份比例：1.16%。
Trails Edge Capital Partners LP持有股份：5.33M，占总股份比例：6.27%。
Morgan Stanley & Co. LLC持有股份：817.82K，占总股份比例：0.96%。
Oliveto (Joseph Gerard)持有股份：2.51M，占总股份比例：2.95%。
RTW Investments L.P.持有股份：2.51M，占总股份比例：2.95%。
Simplify Asset Management Inc持有股份：990.00K，占总股份比例：1.16%。
Trails Edge Capital Partners LP持有股份：5.33M，占总股份比例：6.27%。
Morgan Stanley & Co. LLC持有股份：817.82K，占总股份比例：0.96%。
Oliveto (Joseph Gerard)持有股份：2.51M，占总股份比例：2.95%。
RTW Investments L.P.持有股份：2.51M，占总股份比例：2.95%。
Milestone Pharmaceuticals Inc的前三大股东类型是什么？
Milestone Pharmaceuticals Inc 的前三大股东类型分别是：
Simplify Asset Management Inc
Adage Capital Management, L.P.
Trails Edge Capital Partners LP
Simplify Asset Management Inc
Adage Capital Management, L.P.
Trails Edge Capital Partners LP
有多少机构持有Milestone Pharmaceuticals Inc(MIST)的股份？
截至2025Q3，共有99家机构持有Milestone Pharmaceuticals Inc的股份，合计持有的股份价值约为19.38M，占公司总股份的22.80%。与2025Q2相比，机构持股有所增加，增幅为3.94%。
哪个业务部门对Milestone Pharmaceuticals Inc的收入贡献最大？
在--，--业务部门对Milestone Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
